Skip to main content

Table 2 Cardiorenal effects of SGLT-2i in primary and secondary prevention in T2D

From: Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

SGLT-2 inhibitors EMPA-REGa CANVAS DECLARE VERTIS-CVa SCORED
MACE
 Primary Neutral Neutral Reduced
 Secondary Reduced Reduced Neutral Neutral Reduced
Heart failure
 Primary Reduced Reduced Reduced
 Secondary Reduced Reduced Reduced Reduced Reduced
DKD
 Primary Reduced Reduced Neutral
 Secondary Reduced Reduced Reduced Neutral Neutral
  1. aIncluded T2D patients in secondary prevention only